To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open371.95
High371.95
Low358.7
Prev. Close360.05
Avg. Traded Price364.11
Volume8,946

MARKET DEPTH

info2
Total bid0.00
Total ask0.00
OrdersQtyBid
000
000
000
000
000
AskQtyOrders
000
000
000
000
000

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

358.7012 hours ago
371.9517 hours ago
arrow

LOWER/UPPER CIRCUITS

292.95
439.35
arrow
Kilitch Drugs India Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 31.87%, in the last year to ₹209.48 Cr. Its sector's average revenue growth for the last fiscal year was 10.53%.
noteAnnual Net Profit,rose 80.24% in the last year to ₹26.32 Cr. Its sector's average net profit growth for the last fiscal year was 36.7%.
notePrice to Earning Ratio,is 22.86, lower than its sector PE ratio of 41.8.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 14.81%
Net profit growth 5Y CAGR : 96.79%
Kilitch Drugs (India) Limited is an India-based company engaged in pharmaceutical business. The Company’s services range from manufacturing to marketing a host of formulations in all dosage forms such as solid liquid and parenteral forms. The Company is a manufacturer of antibacterial parenteral formulations. Its products include Carbapenems Cephalosporins Aminoglycosides anti malarials and other anti-infectives. The Company trades in Eyekare Pharmaceuticals products and is located in Mumbai. On February 28 2012 the Company discontinued its manufacturing activity at Paonta Sahib. The Company also transferred certain products by entering into a product transfer agreement with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.
personal

Grow your wealth with more research recommendations

+91